Cargando…
Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis
BACKGROUND: Mesangial proliferative glomerulonephritis (MsPGN) is an epidemic disease with increasing occurrence. As important as mesangial cells, podocytes are key innate cells for MsPGN prognosis and recovery. Renal progenitor cells, located at the urinary pole (UP) of Bowman’s capsule (BC), could...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186716/ https://www.ncbi.nlm.nih.gov/pubmed/32355799 http://dx.doi.org/10.21037/atm.2020.02.58 |
_version_ | 1783527012530388992 |
---|---|
author | Wu, Di Bai, Jiuxu Cui, Shaoyuan Fu, Bo Yin, Zhiwei Cai, Guangyan Chen, Xiangmei |
author_facet | Wu, Di Bai, Jiuxu Cui, Shaoyuan Fu, Bo Yin, Zhiwei Cai, Guangyan Chen, Xiangmei |
author_sort | Wu, Di |
collection | PubMed |
description | BACKGROUND: Mesangial proliferative glomerulonephritis (MsPGN) is an epidemic disease with increasing occurrence. As important as mesangial cells, podocytes are key innate cells for MsPGN prognosis and recovery. Renal progenitor cells, located at the urinary pole (UP) of Bowman’s capsule (BC), could alleviate kidney injury through their capacity to differentiate into podocytes. METHODS: Seventy-two male rats were categorized randomly into the sham (n=24), untreated Thy-1 (n=24) and losartan-treated (n=24) groups. We administered vehicle or losartan (50 mg/kg by gavage) daily to treat rats with anti-thy1.1 nephritis, an ideal model to simulate human MsPGN. Two weeks after the intravenous injection of antibody, urinary protein and blood samples were analyzed, pathological changes were examined, the number of podocytes was determined, and renal progenitor cells were studied. RESULTS: Anti-thy1.1 nephritis was significantly alleviated after losartan treatment, as reported previously and as expected. Compared with the untreated Thy-1 group, the number of podocytes in the losartan group increased, and the area of renal progenitor cells significantly increased. The protein expression of components of the p-ERK pathway was determined during the development of renal progenitor cells differentiating into podocytes. CONCLUSIONS: The data in this paper show the direct glomerular cell action of angiotensin II receptor blocker (ARB) treatment in improving outcomes in anti-thy1.1 nephritis. The positive effects of ARB medication on anti-thy1.1 nephritis were due to an increase in the number of renal epithelial progenitor cells (defined as PECs that expressed only stem cell markers without podocyte proteins). |
format | Online Article Text |
id | pubmed-7186716 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-71867162020-04-30 Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis Wu, Di Bai, Jiuxu Cui, Shaoyuan Fu, Bo Yin, Zhiwei Cai, Guangyan Chen, Xiangmei Ann Transl Med Original Article BACKGROUND: Mesangial proliferative glomerulonephritis (MsPGN) is an epidemic disease with increasing occurrence. As important as mesangial cells, podocytes are key innate cells for MsPGN prognosis and recovery. Renal progenitor cells, located at the urinary pole (UP) of Bowman’s capsule (BC), could alleviate kidney injury through their capacity to differentiate into podocytes. METHODS: Seventy-two male rats were categorized randomly into the sham (n=24), untreated Thy-1 (n=24) and losartan-treated (n=24) groups. We administered vehicle or losartan (50 mg/kg by gavage) daily to treat rats with anti-thy1.1 nephritis, an ideal model to simulate human MsPGN. Two weeks after the intravenous injection of antibody, urinary protein and blood samples were analyzed, pathological changes were examined, the number of podocytes was determined, and renal progenitor cells were studied. RESULTS: Anti-thy1.1 nephritis was significantly alleviated after losartan treatment, as reported previously and as expected. Compared with the untreated Thy-1 group, the number of podocytes in the losartan group increased, and the area of renal progenitor cells significantly increased. The protein expression of components of the p-ERK pathway was determined during the development of renal progenitor cells differentiating into podocytes. CONCLUSIONS: The data in this paper show the direct glomerular cell action of angiotensin II receptor blocker (ARB) treatment in improving outcomes in anti-thy1.1 nephritis. The positive effects of ARB medication on anti-thy1.1 nephritis were due to an increase in the number of renal epithelial progenitor cells (defined as PECs that expressed only stem cell markers without podocyte proteins). AME Publishing Company 2020-03 /pmc/articles/PMC7186716/ /pubmed/32355799 http://dx.doi.org/10.21037/atm.2020.02.58 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Wu, Di Bai, Jiuxu Cui, Shaoyuan Fu, Bo Yin, Zhiwei Cai, Guangyan Chen, Xiangmei Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis |
title | Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis |
title_full | Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis |
title_fullStr | Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis |
title_full_unstemmed | Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis |
title_short | Renal progenitor cells modulated by angiotensin II receptor blocker (ARB) medication and differentiation towards podocytes in anti-thy1.1 nephritis |
title_sort | renal progenitor cells modulated by angiotensin ii receptor blocker (arb) medication and differentiation towards podocytes in anti-thy1.1 nephritis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186716/ https://www.ncbi.nlm.nih.gov/pubmed/32355799 http://dx.doi.org/10.21037/atm.2020.02.58 |
work_keys_str_mv | AT wudi renalprogenitorcellsmodulatedbyangiotensiniireceptorblockerarbmedicationanddifferentiationtowardspodocytesinantithy11nephritis AT baijiuxu renalprogenitorcellsmodulatedbyangiotensiniireceptorblockerarbmedicationanddifferentiationtowardspodocytesinantithy11nephritis AT cuishaoyuan renalprogenitorcellsmodulatedbyangiotensiniireceptorblockerarbmedicationanddifferentiationtowardspodocytesinantithy11nephritis AT fubo renalprogenitorcellsmodulatedbyangiotensiniireceptorblockerarbmedicationanddifferentiationtowardspodocytesinantithy11nephritis AT yinzhiwei renalprogenitorcellsmodulatedbyangiotensiniireceptorblockerarbmedicationanddifferentiationtowardspodocytesinantithy11nephritis AT caiguangyan renalprogenitorcellsmodulatedbyangiotensiniireceptorblockerarbmedicationanddifferentiationtowardspodocytesinantithy11nephritis AT chenxiangmei renalprogenitorcellsmodulatedbyangiotensiniireceptorblockerarbmedicationanddifferentiationtowardspodocytesinantithy11nephritis |